Pure Global AI
NCT06277674Recruiting

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

A Phase II Clinical Trial Evaluating the Efficacy of Cadonilimab in Combination With Pemetrexed and Anlotinib for Treatment of Elderly Patients With T790M-negative Advanced Non-squamous Non-small Cell Lung Cancer Following Resistance to EGFR-TKI.
Guangzhou University of Traditional Chinese MedicinePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
Cadonilimab plus Pemetrexed and Anlotinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Guangzhou University of Traditional Chinese Medicine
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Nov 02, 2023
End date
Jun 01, 2025
Enrollment
20 participants
Primary outcome

ORR(Objective response rate)

Summary

This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and
 CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of
 elderly patients with T790M-negative advanced non-squamous non-small cell lung cancer
 following resistance to EGFR-TKI.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06277674
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06277674 through Pure Global AI's free database. This Phase 2 trial is sponsored by Guangzhou University of Traditional Chinese Medicine and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.